These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25349560)

  • 1. Antimicrobial proteins in intestine and inflammatory bowel diseases.
    Kim JM
    Intest Res; 2014 Jan; 12(1):20-33. PubMed ID: 25349560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial peptides and colitis.
    Ho S; Pothoulakis C; Koon HW
    Curr Pharm Des; 2013; 19(1):40-7. PubMed ID: 22950497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
    Pedersen G
    Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal antimicrobial peptides during homeostasis, infection, and disease.
    Muniz LR; Knosp C; Yeretssian G
    Front Immunol; 2012; 3():310. PubMed ID: 23087688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment.
    Arijs I; De Hertogh G; Lemaire K; Quintens R; Van Lommel L; Van Steen K; Leemans P; Cleynen I; Van Assche G; Vermeire S; Geboes K; Schuit F; Rutgeerts P
    PLoS One; 2009 Nov; 4(11):e7984. PubMed ID: 19956723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease.
    Wehkamp J; Fellermann K; Herrlinger KR; Baxmann S; Schmidt K; Schwind B; Duchrow M; Wohlschläger C; Feller AC; Stange EF
    Eur J Gastroenterol Hepatol; 2002 Jul; 14(7):745-52. PubMed ID: 12169983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial antimicrobial defence of the skin and intestine.
    Gallo RL; Hooper LV
    Nat Rev Immunol; 2012 Jun; 12(7):503-16. PubMed ID: 22728527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial peptides: Defending the mucosal epithelial barrier.
    Johnstone KF; Herzberg MC
    Front Oral Health; 2022; 3():958480. PubMed ID: 35979535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory bowel disease: an impaired barrier disease.
    Jäger S; Stange EF; Wehkamp J
    Langenbecks Arch Surg; 2013 Jan; 398(1):1-12. PubMed ID: 23160753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of intestinal homeostasis by mucosal barriers.
    Okumura R; Takeda K
    Inflamm Regen; 2018; 38():5. PubMed ID: 29619131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-defensins in the gastrointestinal tract.
    Cunliffe RN
    Mol Immunol; 2003 Nov; 40(7):463-7. PubMed ID: 14568393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate Lymphoid Cells in Intestinal Homeostasis and Inflammatory Bowel Disease.
    Saez A; Gomez-Bris R; Herrero-Fernandez B; Mingorance C; Rius C; Gonzalez-Granado JM
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duodenal expression of antimicrobial peptides in dogs with idiopathic inflammatory bowel disease and intestinal lymphoma.
    Nakazawa M; Maeda S; Omori M; Kaji K; Yokoyama N; Nakagawa T; Chambers JK; Uchida K; Ohno K; Yonezawa T; Matsuki N
    Vet J; 2019 Jul; 249():47-52. PubMed ID: 31239164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
    Stecher B
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-Defensin-2 and Beta-Defensin-3 Reduce Intestinal Damage Caused by
    Fusco A; Savio V; Cammarota M; Alfano A; Schiraldi C; Donnarumma G
    J Immunol Res; 2017; 2017():6976935. PubMed ID: 29250559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redox Active Antimicrobial Peptides in Controlling Growth of Microorganisms at Body Barriers.
    Brzoza P; Godlewska U; Borek A; Morytko A; Zegar A; Kwiecinska P; Zabel BA; Osyczka A; Kwitniewski M; Cichy J
    Antioxidants (Basel); 2021 Mar; 10(3):. PubMed ID: 33805777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to Antimicrobial Peptides in Vibrios.
    Destoumieux-Garzón D; Duperthuy M; Vanhove AS; Schmitt P; Wai SN
    Antibiotics (Basel); 2014 Oct; 3(4):540-63. PubMed ID: 27025756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do antimicrobial peptides and complement collaborate in the intestinal mucosa?
    Kopp ZA; Jain U; Van Limbergen J; Stadnyk AW
    Front Immunol; 2015; 6():17. PubMed ID: 25688244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How are the expression patterns of gut antimicrobial peptides modulated by human gastrointestinal diseases? A bridge between infectious, inflammatory, and malignant diseases.
    Dias Bastos PA; Lara Santos L; Pinheiro Vitorino RM
    J Pept Sci; 2018 Mar; 24(3):. PubMed ID: 29542263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial peptides and gut microbiota in homeostasis and pathology.
    Ostaff MJ; Stange EF; Wehkamp J
    EMBO Mol Med; 2013 Oct; 5(10):1465-83. PubMed ID: 24039130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.